ArticleBritish journal of haematology2014

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Amer M Zeidan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.